权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional analysis of the immune landscape in IDH mutant gliomas

IDH 突变神经胶质瘤免疫景观的功能分析

基本信息

批准号：
10196469
负责人：
VIVIANE TABAR
金额：
$ 48.68万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-15 至 2023-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10196469
关键词：
Acute Myelocytic Leukemia Address Affect Antigen Presentation Antigens Autologous Binding Biological Assay Biology CD4 Positive T Lymphocytes Cells ChIP-seq Cholangiocarcinoma Clinical Trials Conditioned Culture Media CpG Islands Data Derivation procedure Disease Progression Down-Regulation Enhancers Environment Enzymes Epigenetic Process Exposure to Failure Genes Genetic Transcription Genome Genomics Glioma Goals Grant Hypermethylation Immune Immunity Immunotherapeutic agent Immunotherapy Impairment Infiltration Inflammatory Innate Immune Response Isocitrate Dehydrogenase Isocitrates Knowledge Leukocytes Link MHC Class II Genes Malignant Glioma Malignant Neoplasms Malignant neoplasm of brain Measures Methods Microglia Molecular Mutation Natural Killer Cells Oncogenes Oncogenic Pathogenicity Pathologic Patients Peripheral Phagocytosis Phase Phenotype Primary Neoplasm Prognosis Public Health Regulon Research Personnel Role Sampling Shapes Source Specific qualifier value T-Cell Activation T-Cell Proliferation T-Lymphocyte Tumor-infiltrating immune cells Work combinatorial cytokine gain of function immune function inhibitor/antagonist innovation interest macrophage migration monocyte mutant mutational status novel prognostic response transcription factor tumor tumor microenvironment tumor-immune system interactions tumorigenesis

项目摘要

PROJECT SUMMARY/ABSTRACT Malignant gliomas are primary brain cancers which can be prognostically stratified on the basis of a single mutation in the gene for isocitrate dehydrogenase (IDH). While gliomas are highly lethal cancers, the IDH mutation confers a significantly better prognosis, compared to IDH wild type gliomas, for unclear reasons. The IDH mutation results in a neomorphic gain of function which produces high levels of the oncometabolite R-2- hydroxyglutarate (2HG) and global genomic hypermethylation. IDH mutant gliomas are characterized by an immune quiescent tumor microenvironment, with significant infiltration with glioma associated macrophages and microglia (GAMs), and high levels of 2HG detected in the microenvironment. The central hypothesis is that 2HG promotes immune quiescence in IDH mutant glioma by specifying GAM function through activation of glioma-associated lineage determining transcription factors, leading to downregulation of antigen presentation capacity of GAMs, and inhibition of peripheral monocyte differentiation. The overarching goal of this study is to investigate how 2HG affects the immune function of GAMs, and how this in turn gives rise to an immune quiescent phenotype. The objective of this proposal is to determine the molecular basis for GAM specification and to develop immune functional assays and novel cellular platforms to interrogate the relationship between 2HG and GAM function in IDH mutant gliomas. The interest of the proposed work lies in providing greater understanding of the biology of the glioma tumor microenvironment in order to inform emerging immunotherapies, most of which have failed in glioma. In addition, IDH inhibitors have entered the clinical trial phase in gliomas, and it is critical to understand whether inhibiting 2HG could have an unintended consequences by reversing immune quiescence and leading to a pro-inflammatory tumor accelerating phenotype.

项目总结/文摘